La Jolla presents results linking antibodies to dsDNA
San Diego-based La Jolla Pharmaceutical has presented analyses showing statistically significant associations between changes from baseline in levels of antibodies to double-stranded DNA (dsDNA) and the relative risk of renal flare in both the Phase II/III and Phase III clinical trials of Riquent.These results, in studies of approximately 500 patients, were presented at the American Society of Nephrology annual meeting.
San Diego-based La Jolla Pharmaceutical has presented analyses showing statistically significant associations between changes from baseline in levels of antibodies to double-stranded DNA (dsDNA) and the relative risk of renal flare in both the Phase II/III and Phase III clinical trials of Riquent.These results, in studies of approximately 500 patients, were presented at the American Society of Nephrology annual meeting.
Analyses of data using Cox's proportional hazards regression model predict that a 50% reduction in antibodies to dsDNA from baseline is associated with a 52% lower risk of renal flare in the Phase II/III trial (p=0.0007) and a 53% lower risk in the Phase III trial (p<0.0001). These findings are consistent with previously released data showing that patients with sustained reductions in antibodies to dsDNA had fewer renal flares. These results will be submitted as part of the company's planned regulatory filings regarding Riquent.
The company is developing Riquent, formerly known as LJP 394, for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. La Jolla is also developing LJP 1082 for the treatment of antibody-mediated thrombosis, a condition in which patients suffer from recurrent stroke, deep-vein thrombosis and other thrombotic events.